Proven results

Clinically proven results with 1 treatment

In 3 clinical studies of people whose frown lines were rated "moderate" or "severe" by a doctor before their treatment with Dysport*:

  • 30 days after treatment, the majority (88%, 85%, and 86% in each of the 3 studies) had their frown lines rated by a doctor as "mild" or "moderate" at maximum frown. For example, a patient could improve from "severe" to "moderate" or from "moderate" to "mild".
  • 30 days after treatment, the majority (74%, 79%, and 82% in each of the 3 studies) rated their own frown lines as "mild" or "moderate" at maximum frown. For example, a patient could improve from "severe" to "moderate" or from "moderate" to "mild".

Used worldwide

Dysport is used for aesthetic purposes in 47 countries. In the United States, Dysport was studied for safety in more than 2,400 U.S. patients, and today over 200,000 women and men have been treated with Dysport.

*Three double-blind, randomized, placebo-controlled, clinical studies evaluated the efficacy of Dysport for use in the temporary improvement of the appearance of moderate to severe glabellar lines. These 3 studies enrolled healthy adults (ages 19-75) with glabellar lines of at least moderate severity at maximum frown. Subjects were excluded if they had marked ptosis, deep dermal scarring, or a substantial inability to lessen glabellar lines, even by physically spreading them apart. The subjects in these studies received either Dysport or a placebo. The total dose was delivered in equally divided aliquots to specified injection sites.

Ipsen Global Regulatory Group. World-Wide Marketing Authorisation for PSUR(s). January 2011. Data on file, Medicis Pharmaceutical Corporation.